Neutralizing anti-IFN-β antibodies -: How much more evidence do we need to use them in practice?

被引：29

作者：

Giovannoni, G

Goodman, A

机构：

[1] UCL, Neurol Inst, Dept Neuroinflammat, London WC1N 3BG, England

[2] Univ Rochester, Dept Neurol, Neuroimmunol Unit, Rochester, NY USA

来源：

NEUROLOGY | 2005年 / 65卷 / 01期

关键词：

D O I：

10.1212/01.wnl.0000172080.54415.f1

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：6 / 8

页数：3

共 16 条

[1] Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years [J].

Bellomi, F ;

Scagnolari, C ;

Tomassini, V ;

Gasperini, C ;

Paolillo, A ;

Pozzilli, C ;

Antonelli, G .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 215 (1-2) :3-8

[2]

Duquette P, 1996, NEUROLOGY, V47, P889

[3] Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) [J].

Durelli, L ;

Verdun, E ;

Barbero, P ;

Bergui, M ;

Versino, E ;

Ghezzi, A ;

Montanari, E ;

Zaffaroni, M .

LANCET, 2002, 359 (9316) :1453-1460

[4] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].

Ebers, GC ;

Rice, G ;

Lesaux, J ;

Paty, D ;

Oger, J ;

Li, DKB ;

Beall, S ;

Devonshire, V ;

Hashimoto, S ;

Hooge, J ;

Kastrukoff, L ;

Krieger, C ;

Mezei, M ;

Seland, P ;

Vorobeychi, G ;

Morrison, W ;

Nelson, J ;

Freedman, MS ;

Chrisie, S ;

Nelson, R ;

Rabinovitch, H ;

Freedman, C ;

Hartung, HP ;

Rieckmann, P ;

Archelos, J ;

Jung, S ;

Weilbach, F ;

Flachenecke, P ;

Sauer, J ;

Hommes, O ;

Jongen, P ;

Brouwer, S ;

McLeod, J ;

Pollard, J ;

Ng, R ;

Sandberg-Wollheim, M ;

Källén, K ;

Nilsson, P ;

Ekberg, R ;

Lundgren, A ;

Jadbäck, G ;

Wikström, J ;

Multanen, J ;

Valjakka, M ;

Carton, H ;

Lissoir, F ;

Declerq, I ;

Vieren, M ;

Peeters, E ;

Dubois, B .

LANCET, 1998, 352 (9139) :1498-1504

[5]

Francis G, 2001, NEUROLOGY, V56, P1628

[6] Results following development of neutralizing antibodies in PRISMS [J].

Francis, GS ;

Rice, GPA ;

Alsop, JC .

NEUROLOGY, 2005, 65 (01) :48-55

[7] Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies [J].

Giovannoni, G .

NEUROLOGY, 2003, 61 (09) :S13-S17

[8]

GNEISS C, 2003, MULT SCLER S9, V9

[9]

HERNDON RM, 1999, INT J MS CARE, V2, P1

[10] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].

Jacobs, LD ;

Cookfair, DL ;

Rudick, RA ;

Herndon, RM ;

Richert, JR ;

Salazar, AM ;

Fischer, JS ;

Goodkin, DE ;

Granger, CV ;

Simon, JH ;

Alam, JJ ;

Bartoszak, DM ;

Bourdette, DN ;

Braiman, J ;

Brownscheidle, CM ;

Coats, ME ;

Cohan, SL ;

Dougherty, DS ;

Kinkel, RP ;

Mass, MK ;

Munschauer, FE ;

Priore, RL ;

Pullicino, PM ;

Scherokman, BJ ;

WeinstockGuttman, B ;

Whitman, RH ;

Baird, WC ;

Fillmore, M ;

Bona, LM ;

ColonRuiz, ME ;

Nadine, BS ;

Donovan, A ;

Bennett, S ;

Kieffer, YM ;

Umhauer, MA ;

Miller, CE ;

Kilic, AK ;

Sargent, EL ;

Schachter, M ;

Shucard, DW ;

Weider, V ;

Catalano, BA ;

Cervi, JM ;

Czekay, C ;

Farrell, JL ;

Filippini, JS ;

Matyas, RC ;

Michienzi, KE ;

Ito, M ;

OMalley, JA .

ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294

← 1 2 →